Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome

Tomoki Suichi¹, Sonoko Misawa¹, Yukari Sekiguchi¹, Kazumoto Shibuya¹, Keigo Nakamura¹, Hiroki Kano¹, Yuya Aotsuka¹, Ryo Otani¹, Marie Morooka¹, Shokichi Tsukamoto¹, Yusuke Takeda¹, Naoya Mimura³, Chikako Ohwada³, Emiko Sakaida³ and Satoshi Kuwabara¹

Abstract:
Objective Immunomodulatory drugs and proteasome inhibitors are therapeutic options for polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. This study aimed to evaluate the efficacy and safety of the combination of ixazomib, lenalidomide, and dexamethasone (IRd) for POEMS syndrome.

Methods Six consecutive patients with POEMS syndrome who were treated with the IRd regimen at Chiba University Hospital between April 2018 and August 2021 were included. Serum M-protein and serum vascular endothelial growth factor (sVEGF) levels, overall neuropathy limitation scales (ONLS), clinical symptoms, and adverse events were assessed.

Results Of the six patients, five had received prior treatments. Patients received a median of 5 cycles (range, 3-28 cycles) of IRd. Following treatment, serum M-protein disappeared in two patients, sVEGF levels returned to normal in two patients, two patients showed a reduction in the ONLS of 1, and clinical symptoms improved in four patients. The median level of sVEGF decreased from 2,395 pg/mL (range, 802-6,120 pg/mL) to 1,428 pg/mL (range, 183-3,680 pg/mL) in three months. Adverse events, including rash, neutropenia, sensory peripheral neuropathy, and nausea, were observed in three patients, which necessitated dose reduction or discontinuation of treatment.

Conclusion IRd can be a therapeutic option for POEMS syndrome, albeit with careful monitoring of adverse events.

Key words: POEMS syndrome, proteasome inhibitors, immunomodulatory drugs, ixazomib, lenalidomide, vascular endothelial growth factor (VEGF)

(Intern Med 61: 2567-2572, 2022)
(DOI: 10.2169/internalmedicine.8786-21)

Introduction

Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare plasma cell proliferative disorder characterized by multiple organ involvement (1). Although the pathogenesis of POEMS syndrome remains unclear, plasma cell dyscrasia and overproduction of vascular endothelial growth factor (VEGF) are believed to play an important role in its patho-
physiology (1, 2). VEGF stimulates vascular permeability and angiogenesis and may be responsible for some symptoms, such as edema/effusion, skin hemangioma, and hepatosplenomegaly (2).

Based on their association with plasma cell dyscrasias, patients with POEMS syndrome have been treated with therapeutic interventions for multiple myeloma, such as high-dose chemotherapy with autologous stem cell transplantation (ASCT) (3-5), alkylating agents (6), immunomodulatory drugs (IMiDs) (7-10), and proteasome inhibitors (PIs) (11-14). These treatments considerably improved the prognosis of patients with POEMS syndrome (15, 16). Thus, new therapeutic agents used for treating multiple myeloma may also be applied to POEMS syndrome, and patients with POEMS syndrome are expected to achieve improved outcomes.

Combination therapies of PIs, IMiDs, and corticosteroids are effective regimens for multiple myeloma (17). Ixazomib is an oral PI used for treating multiple myeloma, and its combination with lenalidomide, an immunomodulatory drug, and dexamethasone, a glucocorticoid, is a therapeutic option for patients with multiple myeloma (18, 19). We therefore speculated that ixazomib, lenalidomide, and dexamethasone (IRd) might also be effective in treating POEMS syndrome. The present study investigated the efficacy and safety of IRd in patients with POEMS syndrome.

Materials and Methods

Patients

This retrospective observational study included six consecutive patients with POEMS syndrome who were treated with IRd at Chiba University Hospital between April 2018 and August 2021. The diagnosis of POEMS syndrome was established based on published diagnostic criteria (20). The IRd regimen comprised a 28-day cycle with oral ixazomib on days 1, 8, and 15; oral lenalidomide on days 1-21; and oral dexamethasone once a week.

The ethics committee of Chiba University Hospital approved off-label use of IRd for POEMS syndrome, and the ethics committee of Chiba University School of Medicine approved this study. All patients provided their written informed consent for the publication of their anonymous data.

Assessments

All patients underwent physical and neurological examinations, blood tests, whole-body computed tomography (CT), and nerve conduction studies as per routine practice. The following variables were assessed: the age, sex, duration of disease, history of previous treatments, clinical symptoms related to POEMS syndrome, overall neuropathy limitations scale (ONLS), and M-protein and VEGF levels. M-protein were assessed in serum using immunofixation. VEGF levels were measured in serum, as the reduction of serum VEGF (sVEGF) levels after treatment significantly correlates with the relapse-free survival and clinical improvement in patients with POEMS syndrome (21). sVEGF levels were measured using an enzyme-linked immunosorbent assay (normal <1,000 pg/mL; Special Reference Laboratory, Tokyo, Japan) (21).

Treatment response

Hematologic, VEGF, neurologic, and other responses were evaluated. The hematologic response included complete response (CRh), defined as a negative result in serum immunofixation, and no-CRH (9). The VEGF response included complete response (CRv), defined as normalization of sVEGF levels (<1,000 pg/mL); partial response (PRv), defined as decrease in sVEGF levels by at least 50%; and stable disease (SDv), defined as not meeting the criteria for either CRv or PRv (9). Neurological response (RN) was defined as a ≥1-point reduction in the ONLS score (9). Other responses included organomegaly, extravascular volume overload, and skin change response, which were defined as the objective improvement in each symptom based on physical examinations and CT findings. Patients who did not meet the criteria for a measurable parameter were excluded from the evaluation of that parameter.

Adverse events

Adverse events were assessed in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

Results

Characteristics of patients

Table 1 shows the characteristics of patients who received IRd. Of the 6 patients, 3 were men, with a median age of 56 (range, 32-75) years old, and the median time from the diagnosis was 56 (range, 2-192) months. POEMS syndrome was newly diagnosed for one patient (case 5), and five patients had been treated previously. Of the five who had been treated previously, the syndrome relapsed in one (case 2) after lenalidomide and dexamethasone (Rd) treatment and in four (cases 1, 3, 4, and 6) after ASCT. Case 6 had received bortezomib and dexamethasone for relapse, and the sVEGF levels normalized before IRd administration. All patients had serum M-protein. All patients had demyelinating polyneuropathy, confirmed using nerve conduction studies, while five patients presented with ONLS scores of ≥1.

Table 2 shows responses to the previous treatment with thalidomide, lenalidomide, and bortezomib. Case 1 was refractory to thalidomide and bortezomib. Although case 2 was refractory to thalidomide, he responded to lenalidomide; case 3 was refractory to both thalidomide and lenalidomide; however, she partially responded to bortezomib. Case 4 was refractory to both lenalidomide and bortezomib. Case 6 responded well to bortezomib.
### Table 1. Baseline Characteristics of Patients.

| Case No. | Sex | Age (months) | History of treatment | M-protein | sVEGF level (pg/mL) | ONLS (Arm/Leg) | Sclerotic bone lesions | Organomegaly | Extravascular volume overload | Skin changes |
|----------|-----|--------------|----------------------|-----------|---------------------|----------------|------------------------|-------------|-----------------------------|-------------|
| 1        | M   | 61           | ASCT, Td, Bd, VCd, 2nd ASCT | IgG-λ     | 3,170               | 2/2            | +                      | -           | -                           | +           |
| 2        | M   | 51           | Td, Rd                | IgA-λ     | 1,680               | 1/1            | +                      | +           | -                           | +           |
| 3        | F   | 61           | Td, Rd, Bd, ASCT      | IgG-λ     | 1,820               | 2/2            | +                      | +           | -                           | +           |
| 4        | M   | 32           | Bd, VRd, ASCT        | IgA-λ     | 2,970               | 0/0†           | +                      | +           | +                           | -           |
| 5        | F   | 75           | None                  | IgA-λ     | 6,120               | 0/2            | +                      | +           | +                           | +           |
| 6        | F   | 43           | Bd, ASCT, 2nd Bd      | IgG-λ     | 802                 | 0/2            | +                      | +           | +                           | +           |

†Demyelinating polyneuropathy confirmed using nerve conduction studies. ASCT: autologous stem cell transplantation, Td: thalidomide and dexamethasone, Rd: lenalidomide and dexamethasone, Bd: bortezomib and dexamethasone, VCd: bortezomib, cyclophosphamide, and dexamethasone, VRd: bortezomib, lenalidomide, and dexamethasone, ONLS: overall neuropathy limitations scale, sVEGF: serum vascular endothelial growth factor.

### Table 2. Response to the Previous Treatment with Thalidomide, Lenalidomide, and Bortezomib.

| Case No. | Thalidomide and dexamethasone | Lenalidomide and dexamethasone | Bortezomib and dexamethasone |
|----------|-------------------------------|--------------------------------|-------------------------------|
|          | Hematologic response | VEGF response | Hematologic response | VEGF response | Hematologic response | VEGF response |
| 1        | No-CR                          | SD                | -                      | -                      | No-CR                 | (No-CR) SD   |
| 2        | No-CR                          | SD                | No-CR                  | CR                    | -                     |              |
| 3        | No-CR                          | SD                | No-CR                  | SD                    | No-CR                 | PR           |
| 4        | -                              | -                 | No-CR†                 | SD†                   | No-CR                 | SD           |
| 5        | -                              | -                 | -                      | -                     | -                     |              |
| 6        | -                              | -                 | CR                     | CR                    |                       |              |

†Addition of cyclophosphamide. †Addition of lenalidomide to bortezomib and dexamethasone. CR: complete response, PR: partial response, SD: stable disease, VEGF: vascular endothelial growth factor.

### Treatment response

Table 3 summarizes the responses to IRd. Patients received a median of 5 cycles (range, 3-28 cycles) of IRd. The initial doses of IRd were as follows: 4 mg ixazomib, 5 mg lenalidomide, and 20 mg dexamethasone for 3 patients (cases 1, 3, and 5); 4 mg ixazomib, 15 mg lenalidomide, and 20 mg dexamethasone for 1 patient (case 2); 4 mg ixazomib, 25 mg lenalidomide, and 20 mg dexamethasone for 2 patients (cases 4 and 6).

Two patients (cases 5 and 6) achieved CRh, and the remaining four had no-CRh. Two cases of CRh were observed at 3 and 10 months. Cases 2, 5, and 6 showed a rapid decrease in sVEGF levels after treatment, whereas cases 1, 3, and 4 showed an inadequate VEGF response (Figure). The median sVEGF levels decreased from 2,395 pg/mL (range, 802-6,120 pg/mL) to 1,428 pg/mL (range, 183-3,680 pg/mL) after 3 months. Of the five patients with elevated sVEGF levels, two (cases 2 and 5) achieved CRh, and three (cases 1, 3, and 4) had SD, at three months. Two patients (cases 2 and 5) achieved Rrh, and both had 1-point reductions in their ONLS score. Three patients (cases 1, 4, and 5) underwent nerve conduction studies before and after IRd. Cases 1 and 5 showed an improvement in median nerve motor conduction velocities (case 1: from 43 m/s to 50 m/s at 4 months, case 5: from 35 m/s to 41 m/s at 3 months). Four patients showed other responses, including three (cases 2, 5, and 6) with an organomegaly response, three (cases 4, 5, and 6) with an extravascular volume overload response, and two (cases 5 and 6) with a skin change response. None of the patients died during follow-up. Cases 1, 3, and 4 showed a poor response to IRd, and subsequently, case 1 received ASCT a third time, and cases 3 and 4 received daratumumab, lenalidomide, and dexamethasone.

### Adverse events

Five patients experienced adverse events (Table 4). Case 2 developed a grade 3 rash on day 4 of the first cycle and suspended IRd. After the rash disappeared completely, IRd was resumed at a reduced dose (I, 3 mg; R, 15 mg; d, 20 mg). Case 5 developed a grade 2 rash during the third cycle. The rash resolved after the patient discontinued ixazomib, so she instead received Rd for six cycles, resulting in an increase in...
sVEGF levels from 875 to 1,770 pg/mL. She resumed IRd at a reduced dose (I, 2.3 mg; R, 15 mg; d, 20 mg), following which sVEGF levels decreased again. Case 5 also developed grade 2 neutropenia and sensory peripheral neuropathy that required a dose reduction of lenalidomide from 15 to 10 mg. Case 4 experienced nausea, resulting in IRd discontinuation.

**Table 3. Response to IRd.**

| Case No. | No. of IRd cycles | Dose of I, R, d (mg) | Hematological response | VEGF response | Neurological response | Organomegaly response | Extravascular volume overload response | Skin change response |
|----------|-------------------|---------------------|-----------------------|---------------|----------------------|-----------------------|----------------------------------------|----------------------|
|          |                   | At 3 months At last visit | At 3 months At last visit | At 3 months At last visit | At 3 months At last visit | At 3 months At last visit | At 3 months At last visit | At 3 months At last visit |
| 1        | 4                 | 4, 5, 20            | No-CR No-CR SD SD     | No No         | - -                  | - -                   | No No                   | No No                   |
| 2        | 21                | 4 (3), 15, 20       | No-CR No-CR CR CR     | No Yes        | No Yes               | No Yes                | No No                   | No No                   |
| 3        | 3                 | 4, 5, 20            | No-CR No-CR SD SD     | No No         | No No               | No No                 | No No                   | No No                   |
| 4        | 3                 | 4, 25, 20           | No-CR No-CR SD SD     | - -           | No No               | Yes Yes               | Yes Yes                 | - -                   |
| 5        | 28                | 4 (2.3), 5 (10-15), 20 | No-CR CR PR           | Yes Yes       | Yes Yes             | Yes Yes              | Yes Yes                 | No Yes                 |
| 6        | 6                 | 4, 25, 20           | CR CR                 | - -           | No No               | Yes Yes               | Yes Yes                 | Yes Yes                 |

†Adjusted dose after adverse events. IRd: ixazomib, lenalidomide, and dexamethasone, CR: complete response, PR: partial response, SD: stable disease, VEGF: vascular endothelial growth factor

**Figure.** Serial changes in the levels of serum vascular endothelial growth factor. Dotted lines indicate the upper limit of the normal range. †Discontinuation of IRd. IRd: ixazomib, lenalidomide, and dexamethasone, sVEGF: serum vascular endothelial growth factor

To our knowledge, this is the first case series of IRd in patients with POEMS syndrome. IRd was effective in three of six patients and contributed to the disappearance of serum M-protein, decreased sVEGF levels, and clinical improvement. However, this was accompanied by alarming adverse events such as rash, nausea, neutropenia, and sensory peripheral neuropathy, which were handled by reducing the treatment intensity or discontinuing treatment. Our results suggest that IRd may be a therapeutic option for POEMS syndrome.

PIs and IMiDs are currently used to treat POEMS syndrome (16). The efficacy of bortezomib, an injectable PI, for POEMS syndrome has been reported in case series/reports (11-14). The IMiDs, thalidomide and lenalidomide, have been administered to patients with POEMS syndrome, and their efficacies have been demonstrated in several clinical trials (7-10). Although each agent is a promising therapy for POEMS syndrome, the efficacy of their combination has not been investigated. The present study is the first to show the potential efficacy of IRd, a combination of PIs and IMiDs, in POEMS syndrome. Furthermore, IRd is suitable for long-term treatment, as all of the agents are administered as oral drugs.

Ixazomib selectively binds to the β5 site of the S20 proteasome, inhibits its chymotrypsin-like activation, and induces the accumulation of ubiquitinated proteins (22). This induces apoptosis in the tumor cells. Cereblon is the primary target of lenalidomide. The binding of lenalidomide to cereblon causes ubiquitination of IKZF1 and IKZF3, promoting their degradation and resulting in anti-tumor effects (23, 24). The mechanisms of action of ixazomib and lenalidomide differ, which is useful for treating POEMS syndrome. Therefore, IRd can be effective for a broad range of patients. In addition, ixazomib has been shown to exert synergistic effects when used with lenalidomide in preclinical studies (25). The TOURMALINE-MM1 study, a phase 3 trial of ixazomib-Rd versus placebo-Rd in patients with relapsed/refractory multiple myeloma, showed that the addition of ixazomibe to Rd prolonged the progression-free survival (18). We previously conducted a clinical trial of Rd in five patients with POEMS syndrome (10); however, we were unable to compare the results of the present study with those of our previous clinical trial because the patient backgrounds differed between the two studies.
According to the TOURMALINE-MM1 study, the common adverse events related to IRd included thrombocytopenia, neutropenia, nausea, vomiting, diarrhea, constipation, rash, peripheral neuropathy, peripheral edema, and back pain (18, 26). These adverse events were generally mild and manageable, although sometimes they had to be managed with supportive care and dose reductions (26). In the present study, neutropenia, nausea, rash, and peripheral neuropathy affected the treatment course. Thus, awareness regarding potential toxicities is critical for handling them appropriately.

Several limitations associated with the present study warrant mention. This was a retrospective study conducted on a small number of patients over a short period. Of the six cases, three (cases 1, 3, and 4) received only three or four cycles of treatment. The reason underlying the poor response to IRd may be the short duration of treatment, or the patients may have been refractory to the previous IMiDs and/or PIs and consequently were refractory to IRd as well (Table 2). In contrast, the patients who had had a good response to IRd, except for the newly diagnosed patient (case 5), were sensitive to the previous lenalidomide (case 2) and bortezomib (case 6). The doses of ixazomib and lenalidomide differed among cases, which was an important issue; therefore, the use of IRd in treating POEMS syndrome bears caution.

In conclusion, our results indicated that IRd was effective in some patients with POEMS syndrome. However, the treatment can be accompanied by hematological, gastrointestinal, neurological, and dermatological toxicities. An open-label phase 2 clinical trial is underway in the USA (ClinicalTrials.gov number, NCT02921893), and the efficacy and safety of IRd for POEMS syndrome are expected to be validated.

The ethics committee of Chiba University Hospital approved off-label use of ixazomib, lenalidomide, and dexamethasone for POEMS syndrome. The ethics committee of the Chiba University School of Medicine approved this study.

All patients provided their written informed consent.

The authors state that they have no Conflict of Interest (COI).

### References

1. Dispenzieri A. POEMS syndrome: 2021 update on diagnosis, risk stratification, and management. Am J Hematol 96: 872-888, 2021.
2. Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347: 702, 1996.
3. D’Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood 120: 56-62, 2012.
4. Li J, Duan MH, Wang C, et al. Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome. Leukemia 31: 1375-1381, 2017.
5. Ohwada C, Sakaeda E, Kawajiri-Manako C, et al. Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood 131: 2173-2176, 2018.
6. Li J, Zhang W, Jiao L, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 117: 6445-6449, 2011.
7. Misawa S, Sato Y, Katayama K, et al. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15: 1129-1137, 2016.
8. Nozza A, Terenghi F, Gallia F, et al. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol 179: 748-755, 2017.
9. Li J, Huang XF, Cai QQ, et al. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polynuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol 93: 803-809, 2018.
10. Suichi T, Misawa S, Nagashima K, et al. Lenalidomide treatment for thalidomide-refractory POEMS syndrome: a prospective single-arm clinical trial. Intern Med 59: 1149-1153, 2020.
11. He H, Fu W, Du J, Jiang H, Hou J. Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol 181: 126-128, 2018.
12. Riva M, Lessi F, Bono T, et al. Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients. Leuk Lymphoma 60: 2067-2070, 2019.

### Table 4. Adverse Events.

| Case No. | Grade 1 | Grade 2 | Grade 3 |
|----------|---------|---------|---------|
| 1        | ALT elevation, AST elevation | - | - |
| 2        | - | - | Rash† |
| 3        | - | - | - |
| 4        | - | Nausea† | - |
| 5        | - | Rash†, sensory peripheral neuropathy† | Neutropenia† |
| 6        | Somnolence | - | - |

†Causes of dose reduction or withdrawal. ALT: alanine aminotransferase, AST: aspartate aminotransferase.
13. Kaygusuz I, Tercan H, Cetiner M, Kocakay O, Uray A, Bayik M. Bortezomib: a new therapeutic option for POEMS syndrome. Eur J Haematol 84: 175-177, 2010.
14. Li J, Zhang W, Kang WY, Cao XX, Duan MH, Zhou DB. Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure. Leuk Lymphoma 53: 2527-2529, 2012.
15. Kourielis TV, Buadi FK, Kumar SK, et al. Long-term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience. Am J Hematol 91: 585-589, 2016.
16. Suichi T, Misawa S, Beppu M, et al. Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology 93: e975-e983, 2019.
17. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95: 548-567, 2020.
18. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374: 1621-1634, 2016.
19. Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 137: 3616-3628, 2020.
20. Suichi T, Misawa S, Sato Y, et al. Proposal of new clinical diagnostic criteria for POEMS syndrome. J Neurol Neurosurg Psychiatry 90: 133-137, 2019.
21. Misawa S, Sato Y, Katayama K, et al. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study. BMJ Open 5: e009157, 2015.
22. Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK. Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther 10: 217-226, 2016.
23. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343: 301-305, 2014.
24. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343: 305-309, 2014.
25. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17: 5311-5321, 2011.
26. Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol 178: 571-582, 2017.